TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~Part A only:~- Healthy male subjects aged between 18 and 55 years.~Part B only:~* Healthy male and female subjects aged between 18 and 55 years.~* Women of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 1 pre-dose of the first period. They must consistently and correctly use a highly effective method of contraception, or be sexually inactive, or have a vasectomized partner.~* Women of nonchildbearing potential (i.e., postmenopausal, XY genotype, Turner syndrome, uterine agenesis).~Part A and B:~* Signed informed consent prior to any study-mandated procedure.~* Body mass index of 18.0 to 30.0 kg/m2 (inclusive) at Screening. Body weight at least 50.0 kg at Screening and prior to first study treatment administration.~* Healthy on the basis of medical history, physical examination, cardiovascular assessments and clinical laboratory tests.~Exclusion Criteria:~Part B only:~* Known hypersensitivity to moxifloxacin or any of its excipients.~* Pregnant or lactating women.~* Women planning to become pregnant.~Part A and B:~* Previous exposure to lucerastat.~* Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.~* History or presence of rhythm disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Part A: Treatment 1 (Type: EXPERIMENTAL): A single oral dose of 2000 mg lucerastat on Day 1 and of 4000 mg lucerastat on Day 3
- Part A: Treatment 2 (Type: PLACEBO_COMPARATOR): A single oral dose of placebo on Day 1 and 3
- Part B: Treatment A (Type: ACTIVE_COMPARATOR): A single oral dose of 400 mg moxifloxacin
- Part B: Treatment B (Type: EXPERIMENTAL): A single oral dose of 1000 mg lucerastat
- Part B: Treatment C (Type: EXPERIMENTAL): A single oral dose of 4000 mg lucerastat
- Part B: Treatment D (Type: PLACEBO_COMPARATOR): A single oral dose of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes。~Exclusion Criteria:~* Type 2 diabetes with acute diabetic complications.~* Type 1 diabetes.~* Other diseases affecting cognitive function (congenital dementia,brain trauma,severe heart dysfunction,severe kidney dysfunction,severe lung dysfunction,epilepsy,severe hypoglycemic coma,cerebrovascular disease,ischemic heart disease,etc).~* Alcohol abuse,mental illness and psychoactive substance abuse.~* History of thyroid disease.~* Any surgical or medical conditions that significantly influence absorption, distribution, metabolism or excretion of the intervention drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: ACTIVE_COMPARATOR): 12 weeks of liraglutide treatment at adjusting dose, up to 1.8mg/day Drug: liraglutide
- Placebo (Type: PLACEBO_COMPARATOR): 12 weeks of Placebo treatment at adjusting dose Drug:Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women, still with uterus, planning total hysterectomy as part of surgical repair for pelvic organ prolapse~* Symptomatic anterior and/or apical vaginal prolapse greater than or equal to Stage 2 (i.e., bulge extends to at least 1 cm of the hymen or beyond)~* Women between 1 and 10 years after menopause. Menopause is defined as one year of amenorrhea or surgical ovariectomy.~* Age 40-70 years old~* No estrogen replacement therapy in the last 1 month~* Physically capable of daily application of vaginal cream~Exclusion Criteria:~* BMI \>35~* Prior surgical repair of prolapse involving the vaginal cuff.~* Prior total hysterectomy~* Premenopausal or postmenopausal \>10 years~* Prior steroid hormone replacement therapy of duration \>1 month (oral or vaginal estrogen, testosterone or corticosteroids)~* History of connective tissue disease (Ehlers-Danlos, Marfan, etc)~* History of vaginal radiation~* Contraindications for estrogen replacement therapy (current, or history of, spontaneous deep vein thrombosis, stroke, coronary artery disease, breast or endometrial cancer)~* Concurrent use of steroid cream for treatment of Lichen sclerosis~* Recent history (within last month) of vaginal infection or vaginitis~* Current tobacco use

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Premarin (Type: EXPERIMENTAL): Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant gestational age \>= 28 weeks~* Systolic blood pressure \>=160 mm Hg OR a diastolic blood pressure of \>=110 mm Hg measured twice more than 15 minutes apart~* Able to swallow pills~* \>= 18 years~Exclusion Criteria:~* Indication for emergent cesarean or known fetal anomaly~* Anti-hypertensive therapy received in the past 12 hours~* History of eclampsia or other adverse CNS complication (e.g., stroke or PRES) in this pregnancy~* Actively wheezing at time of enrollment or history of asthma complications~* Known coronary artery disease or type I DM with microvascular complications or signs of heart failure or clinical dissection of the aorta

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Nifedipine (Type: ACTIVE_COMPARATOR): Women will receive an initial dose of oral nifedipine 10mg. If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 10mg dose can be provided each hour for two additional doses (30 mg total).
- Methyldopa (Type: EXPERIMENTAL): Women will receive an initial dose of oral methyldopa 1000mg. No additional escalation in dose in the first 6 hours will be given.
- Labetalol (Type: EXPERIMENTAL): Women will receive an initial dose of oral labetalol 200mg. If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 200mg dose can be provided each hour for two additional doses (600 mg total).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Main inclusion criteria:~- Patient suffering from either primary progressive or secondary progressive multiple sclerosis without relapse within 2 years before inclusion according to the revised McDonald's criteria.~Main exclusion criteria:~- Patient suffering from a disease other than MS that would better explain the patient's neurological clinical signs and symptoms and/or MRI lesions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Experimental Arm A (Type: EXPERIMENTAL): Participants receive masitinib (4.5 mg/kg/day), given orally twice daily.
- Experimental Arm B (Type: EXPERIMENTAL): Participants receive masitinib (4.5 mg/kg/day), given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment.
- Placebo Comparator A (Type: PLACEBO_COMPARATOR): Participants receive placebo given orally twice daily.
- Placebo Comparator B (Type: PLACEBO_COMPARATOR): Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Serum Levels of C Type Natriuretic Peptide in Different Reproductive Periods

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy~* Regular cyclic menstruation for reproductive age group~Exclusion Criteria:~* No systemic disease(cardiac, renal...etc)~* Smoking~* Drug usage~* Pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Reproductive age women (Type: ACTIVE_COMPARATOR): The healthy women between 18-40 years old.
- Perimenopausal women (Type: ACTIVE_COMPARATOR): The healthy women between 40-49 years old.
- Postmenopausal women (Type: ACTIVE_COMPARATOR): The healthy women that has been in to menopause more than a year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study Assessing Blood Pressure and Other Outcomes Post-treatment in Patients With Primary Aldosteronism

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~i. Legally capacitated ii. 21-80 years iii. Diagnosed with primary aldosteronism iv. Patient is willing, or has undergone, adrenal surgery (in case of unilateral disease), or medical treatment (if not keen for surgery, medically unfit, or has bilateral disease)~Exclusion Criteria:~i. Unable to give consent ii. \< 21 years or \> 80 years iii. Glucocorticoid remediable aldosteronism iv. Adrenal Carcinoma v. Severe or terminal medical condition(s) that in the view of the investigator prohibits participation in the study or interferes with possible treatment or health-related quality of life, e.g. cancer, end-stage liver disease, end stage renal failure vi. Female patients who are pregnant, intending to become pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Medical Treatment (Type: None): Patients who undergo medical treatment, in view of bilateral PA, or unilateral PA not keen for surgery, or indeterminate (lack of localisation on tests)
- Surgical Treatment (Type: None): Patients with unilateral PA who underwent adrenalectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females \> 16 and \< 80 years of age.~2. Blood pressure \< 140/90 mmHg.~3. Serum creatinine ≤ 1.5 mg/dl and/or creatinine clearance ≥ 60 ml/min.~4. Bleeding time, prothrombin time, partial thromboplastin time, platelets and fibrinogen in the normal range.~Exclusion Criteria:~1. Biopsy of transplant kidney~2. Poorly controlled hypertension~3. Single kidney~4. Renal cancer~5. Hydro/pyonephrosis~6. Renal size significantly reduced~7. Severe obesity~8. Coagulation disorder~9. Serum creatinine \> 1.5 mg/dl and/or creatinine clearance \< 60 ml/min

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Saline solution (Type: PLACEBO_COMPARATOR): patients treated with 1 ml of s.c. saline solution
- DDAVP (Type: EXPERIMENTAL): treated with DDAVP (0.3 mcg/Kg s.c.) 1 hour before renal biopsy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Beta-Cell Dysfunction and Insulin Resistance Among Italian Patients With Type 2 Diabetes (MK-0000-113)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Physician diagnosis of type 2 diabetes mellitus by American Diabetes Association (ADA) criteria~* Oral hypoglycemic drug therapy for ≥1 year~* Continuous care at the clinic (at least 2 visits) for at least one year~* Medical records completed with a minimum core data set~* Completed consent form~Exclusion Criteria:~* Participation in a clinical trial in the previous 1 year~* Currently using insulin~* Type 1 diabetes~* Pregnancy

- Gender: ALL
- Minimum Age: 41 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All Participants (Type: None): Participants receiving routine care under a diabetologist.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Continue to meet all demographic and procedural~inclusion criteria of the A7501013 trial to enter into~this extension trial.~* Have demonstrated an acceptable degree of compliance~and completed the A7501013 trial, and would benefit~from continued treatment according to the investigator.~Exclusion Criteria:~* Have an uncontrolled, unstable clinically significant~medical condition.~* Have been judged to be medically noncompliant in the~management of their disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- asenapine (Type: EXPERIMENTAL): None
- olanzapine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged greater than or equal (\>=) 18 years~* Fibromyalgia diagnosed at least one year before~* History of generalized pain and at least 16 positive tender points (1990 American College of Rheumatology \[ACR\] criteria)~* Body Mass Index (BMI) less than or equal to(=\<) 32~* Normal GH stimulation test (insulin)~* Stable (\>= 3 months unchanged) standard treatment with amitriptyline (10-50 milligram per day \[mg/day\]) plus selective serotonin reuptake inhibitor (10-40 mg/day) plus tramadol (25-400 mg/day)~* Active rehabilitation program during the previous year (at least 30 minutes/day)~* Fibromyalgia Impact Questionnaire (FIQ) score \>=75~* IGF-1 serum level =\< 150 nanogram/milliliter (ng/mL) otherwise =\< 2 SD of the local lab normality)~* Normal response to IGF-1 generation test~* Chronic Fatigue Symptoms (Multidimensional Assessment of Fatigue \[MAF\])~* Effective anti-conception~* Willingness to comply with the protocol~* Written Informed consent~Exclusion Criteria:~* Major psychiatric condition~* Rheumatic disease, including systemic lupus erythematosus (SLE)~* Previous or current malignancies, active or inactive~* Clinical history intracranial space occupying lesion~* Reactive or secondary (rheumatoid arthritis \[RA\], osteoarthritis) fibromyalgia syndrome (FMS)~* Antinuclear antibody (ANA) greater than or equal 1:80~* Abnormal Creatine phosphokinase (CPK) or aldolase serum levels~* Not controlled thyroid disease in the last 3 months (free Thyroxine \[T4\] and Thyrotrophin-stimulating hormone \[TSH\] serum levels)~* Diabetes mellitus~* Adrenal gland disease (any abnormal cortisolemia, will be confirmed by 24-hour cortisoluria)~* Pregnancy or breast feeding~* Known to be hypersensitive to somatotropin or any of the excipients

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Saizen® (Type: ACTIVE_COMPARATOR): None
- Placebo + Saizen® (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV RNA greater than or equal to 1000 c/mL.~* Failed/Failing protease inhibitor based antiretroviral therapy.~* Stable antiretroviral therapy for greater than or equal to 30 days prior to screening.~* Negative Serum Pregnancy Test.~* GFR by Cockcroft Gault greater than or equal to 80 mL/min.~* AST \& ALT less than or equal to 2.5x ULN.~* Total Bilirubin less than or equal to 1.5 mg/dL.~* Albumin greater than 3.5 mg/dL.~* Prothrombin Time INR 1.0-1.4~* Platelets greater than or equal to 50,000.~* Hemoglobin greater than or equal to 8.0 mg/dL.~* Absolute Neutrophil Count greater than or equal to 1000.~Exclusion Criteria:~* New AIDS defining condition within 30 days of baseline.~* Prior treatment with HIV-1 integrase inhibitor (except patients from 183-101).~* Ascites or encephalopathy.~* Breast Feeding.~* Cancer Diagnosis (besides Kaposi Sarcoma or Basal Cell Carcinoma).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Therapy in Treatment of Patients With Helicobacter Pylori Infection: Concomitant Versus Hybrid Therapy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Helicobacter pylori infection (documented by: positive antigen stool test, or positive urease rapid test obtained during upper endoscopy, or Helicobacter pylori in histological finding, or positive C-urea breath test; according to recent Maastricht V guidelines;~* written informed consent~Exclusion Criteria:~* age under 18~* previously treatment of Helicobacter pylori infection~* malignancy of stomach or other site~* history of taking proton pump inhibitors, H2 antagonist, bismuth or antibiotics (amoxicillin, metronidazole, clarithromycin) in previous month~* significant underlying disease (renal failure, psychiatric disorders)~* history of allergic reactions to any medications used in study~* refuse to participate in study~* breastfeeding and pregnancy~* quitting the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Concomitant therapy (Type: ACTIVE_COMPARATOR): Amoxicillin ('Amoksicilin') 1 g bid, metronidazole ('Medazol')500 mg bid, clarithromycin ('Makcin')500 mg bid and esomeprazole ('Emanera')40 mg bid for 14 days.
- Hybrid therapy (Type: ACTIVE_COMPARATOR): Amoxicillin ('Amoksicilin') 1 g bid and esomeprazole ('Emanera') 40 mg bid for 14 days, with metronidazole ('Medazol')500 bid and clarithromycin ('Makcin') 500 mg bid for the last 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signs of a bleeding in the stomach~* One endoscopically confirmed bleeding ulcer in the stomach or duodenum~Exclusion Criteria:~* Malignancy or other advanced disease.~* Major cardiovascular event.~* Severe hepatic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete